0.9478USD-11.42%Mkt Cap: 119.44M USDP/E: —Last update: 2026-05-26
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap119.44M USD
Enterprise Value74.58M USD
Revenue (TTM)3.17M USD
Gross Profit3.17M USD
Net Income (TTM)-29.67M USD
Revenue/Share0.0310 USD
Last Price0.9478 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.65
PEG—
EV/EBITDA-2.21
EV/Revenue23.53
P/S42.21
P/B3.17
EPS (TTM)-0.27
EPS (Forward)-0.23
52W Range
0.387016% of range3.870
52W High3.870 USD
52W Low0.3870 USD
Profitability
Gross Margin100.00%
Oper. Margin-488.23%
EBITDA Margin0.00%
Profit Margin-1817.09%
ROE-89.89%
ROA-50.62%
Growth
Revenue Growth893.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.71M USD
CapEx (TTM)88.00K USD
FCF Margin-106.75%
FCF Yield-2.83%
Net Debt-39.46M USD
Net Debt/EBITDA1.17
Balance Sheet
Debt/Equity0.13
Current Ratio3.40
Quick Ratio3.28
Book Value/Sh0.3380 USD
Cash/Share0.4340 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)7.500 USD
Target Range5.000 USD – 11.00 USD
# Analysts4
Ownership
Shares Out.99.91M
Float70.78M
Insiders5.64%
Institutions47.44%
Short Interest
Short Ratio8.3d
Short % Float9.24%
Short % Out.8.96%
Shares Short8.95M
Short (prev mo.)10.11M
Technical
SMA 500.9764 (-2.9%)
SMA 2001.140 (-16.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)956.86K
Avg Vol (10d)1.35M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—